Skip to main content

Elevance Health, Inc. guidance

  • ELV · NYSE
  • Insurance
  • Managed Health Care
  • S&P 500
$446.28+3.86%Close 16 Nov 2026 · Market value $94.62B

In its results release of 21 Oct 2026 (Q3 FY2026), Elevance Health, Inc. gave 3 forecasts in figures, among them EPS of at least $22.00 for FY2026.

Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.

Latest guidance given with Q3 FY2026 results, 21 Oct 2026

MeasurePeriodGuidanceAs stated
EPS · ReaffirmedFY2026At least $22.00During these meetings, Company officers will reaffirm the Company’s shareholders’ earnings guidance for full year 2026 to be at least $22.00 per diluted share, including approximately $7.00 per diluted share of net unfavorable items
EPS · Adjusted · RaisedFY2026At least $29.00FY 2026 diluted EPS 1 guidance raised to at least $22.00; adjusted diluted EPS 2 guidance raised to at least $29.00 on continued operating momentum
Operating cash flow · RaisedFY2026At least $6.50BFY 2026 operating cash flow guidance raised to at least $6.5 billion

Source: the company's earnings release.

Guidance against results above 1 · within 0 · below 1

The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.

MeasurePeriodLast guidanceRevisionsDeliveredResult
EPS · GAAPFY2026At least $22.30Given once—To come
EPS · AdjustedFY2026At least $29.00Raised twice—To come
EPSFY2026At least $22.00Raised twice—To come
Operating cash flowFY2026At least $6.50BRaised twice—To come
Tax rate · AdjustedFY202622% to 24%Given once—To come
EPS · GAAPFY2025About $24.10Lowered once$25.21Above the range
EPS · GAAPFY2024About $26.50Given once$25.68Below the range

ELV in the terminal

Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.